Growth hormone deficiency pathophysiology: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
 
(28 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Growth hormone deficiency}}
{{Growth hormone deficiency}}
{{CMG}}; {{AE}}  
{{CMG}}; {{AE}} {{MAD}}
 
==Overview ==
The [[Somatotrophs|somatotroph cells]] of the [[Anterior pituitary gland|anterior pituitary organ]] produce [[growth hormone]] ([[Growth hormone|GH]]). The most widely studied impact of growth hormone is increasing [[weight]]. [[Growth hormone|GH]] causes [[epiphyseal plate]] broadening and [[ligament]] development. [[Growth hormone|GH]] deficiency results in alterations in the [[physiology]] of different systems of the body, manifesting as altered [[lipid metabolism]], increased [[Subcutaneous tissue|subcutaneous]] [[visceral]] [[fat]], decreased [[muscle mass]], decreased [[bone density]], low exercise performance, and reduced quality of life. The hereditary premise of inborn growth hormone deficiency relies upon numerous factors; POU1F1 quality transformations are the most widely recognized hereditary reason for the joined [[pituitary hormone]] lack. Quality [[Deletion (genetics)|deletions]], [[Frameshift mutation|frameshift]] transformations, and jabber changes of GH1 quality have been described as reasons for familial GHD.


==Overview==
==Pathophysiology==
==Pathophysiology==
* The [[Somatotroph|somatotroph cells]] of the [[anterior pituitary gland]] produce [[growth hormone]].<ref name="pmid8879986">{{cite journal| author=Cuttler L| title=The regulation of growth hormone secretion. | journal=Endocrinol Metab Clin North Am | year= 1996 | volume= 25 | issue= 3 | pages= 541-71 | pmid=8879986 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8879986  }}</ref>
* They are regulated by two [[Hypothalamus|hypothalamic]] hormones; [[GHRH|GH-releasing hormone]] ([[GHRH]]) stimulates and [[somatostatin]] inhibits them.


==Genetics==
* GH increases [[body mass]] by:
'''MOLECULAR GENETICS OF GROWTH HORMONE DEFICIENCY'''
**Increasing total body [[protein]] content and is associated with an increase in [[amino acid]] incorporation into [[cartilage]] and [[bone]].<ref name="pmid13319878">{{cite journal| author=MURPHY WR, DAUGHADAY WH, HARTNETT C| title=The effect of hypophysectomy and growth hormone on the incorporation of labeled sulfate into tibial epiphyseal and nasal cartilage of the rat. | journal=J Lab Clin Med | year= 1956 | volume= 47 | issue= 5 | pages= 715-22 | pmid=13319878 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=13319878  }}</ref>
 
**Stimulation of l[[Lipolysis|ipolysis]] decreasing total body [[fat]] content.
30 percent of GHD is genetic [9,10].  
**Increasing [[bone mass]] by stimulating skeletal [[insulin-like growth factor-I]], causing [[hypertrophy]] of [[osteoblasts]], bone remodeling, and [[mineralization]].  
 
**Decreasing the expression of [[adipocyte]] maturation regulators ([[CEBPA|''C/EBPα'',]] ''[[PPAR|PPARγ]]'') and prominent genes related to [[lipid]] synthesis such as ''[[FAS ligand|FAS]]'' and ''[[FABP1|FABP]].''
The ''POU1F1'' gene
**Increasing the [[Messenger RNA|mRNA]] expression of ''[[adiponectin]]'' and ''[[UCP1]]'' in mature [[adipocytes]] causing [[epiphyseal plate]] widening and [[cartilage]] growth.<ref name="pmid15689575">{{cite journal| author=Veldhuis JD, Roemmich JN, Richmond EJ, Rogol AD, Lovejoy JC, Sheffield-Moore M et al.| title=Endocrine control of body composition in infancy, childhood, and puberty. | journal=Endocr Rev | year= 2005 | volume= 26 | issue= 1 | pages= 114-46 | pmid=15689575 | doi=10.1210/er.2003-0038 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15689575  }}</ref>
 
is responsible for pituitary-specific transcription of genes for GH, prolactin, thyrotropin, and the growth hormone releasing hormone (GHRH) receptor [11,12].  
 
''PROP1'' mutations result in failure to activate ''POU1F1/Pit1'' gene expression and probably cause pituitary hypoplasia and/or familial multiple pituitary hormone deficiency [17]; paradoxical cystic hyperplasia of the pituitary also has been reported [18]. This is the most common known genetic cause of combined pituitary hormone deficiency [19,20].
 
GHRH receptor gene defects
 
Children with mutations in the GHRH receptor gene have undetectable GH release during standard provocative tests and after exogenous GHRH administration, but they respond to GH treatment.
 
Deletions and mutations of ''GH1'' 
 
''GH1'' is the gene encoding GH, located on chromosome 17. Gene deletions, frameshift mutations, and nonsense mutations of ''GH1'' have been described as causes of familial GHD [25].
 
Syndrome of bioinactive GH


A diagnosis of the syndrome of bioinactive GH has been proposed for short children with a phenotype that resembles that of isolated GHD, with normal or slightly elevated basal GH levels in combination with low insulin-like growth factor I (IGF-I) concentrations that increase after treatment with exogenous GH. True molecular abnormalities involving a mutant GH molecule have rarely been reported [26,27]
*[[Growth hormone|GH]] deficiency results in alterations in the [[physiology]] of different systems of the body, manifesting as altered [[lipid metabolism]], increased [[Subcutaneous tissue|subcutaneous]] [[visceral]] [[fat]], decreased [[muscle mass]], decreased [[bone density]], low exercise performance, and reduced quality of life.


'''Laron syndrome'''
== Regulation of growth hormone secretion ==
* The secretion of [[growth hormone]] is controlled by a complex regulatory system. Primarily, it is controlled by two [[hormones]]; [[Growth hormone releasing hormone|GH-releasing hormone]] and [[somatostatin]].


It is caused by homozygous or compound heterozygous mutations in the growth hormone (GH) receptor gene; a variety of mutations have been identified, most of which affect the extracellular GH-binding region of the receptor [2-4].
* The [[adenylate cyclase]]-[[cyclic AMP]]-[[protein kinase A]] plays a major role in the control of GH secretion by [[Growth hormone releasing hormone|GH-releasing hormone]].
* GH gene expression is also of importance in determining the [[Growth hormone|GH]] response.
* GH secretion is [[Pulsatile flow|pulsatile]]; between pulses, serum GH concentration may be undetectable. It is thought that the pulses of GH release are mediated by the reduction in inhibition by [[somatostatin]] with an increase of [[GHRH]].


'''GH receptor signal transduction''' 
* The [[glucocorticoids]] play a principal role in the functional maturation of [[Growth hormone|GH]] cells in the fetal [[Pituitary gland|pituitary glands]], inducing [[Growth hormone|GH]] and [[Growth hormone-releasing hormone|GHRH-receptor]] [[gene expression]], and development of the [[Growth hormone|GH]] secretory system.
* During [[puberty]], there is a temporary increase in [[Growth hormone|GH]] secretion with a subsequent return to the normal values in early adulthood.
[[File:1809 Hormonal Regulation of Growth.jpg|500px|center|thumb|Growth hormone secretion regulations, source: By OpenStax College - Anatomy & Physiology, Connexions Web site. httpcnx.orgcontentcol114961.6, Jun 19, 2013., CC BY 3.0, httpscommons.wikimedia.orgwindex.phpcurid=30148146]]
== Molecular effects of growth hormone on cells ==
* [[Growth hormone]] acts by binding to the [[Receptor (biochemistry)|receptor]] [[homodimer]] in the [[liver]].
* The [[Receptor (biochemistry)|receptor]] consists of an [[extracellular]] [[Ligand (biochemistry)|ligand-binding]] [[Domain (biology)|domain]] and a [[Cytoplasm|cytoplasmic]] signaling part.
* GH acts to stimulate hepatic synthesis and secretion of [[Insulin-like growth factor-I|insulin-like growth factor-1]] ([[Insulin-like growth factor-I|IGF-1]]).
* [[Insulin-like growth factor-I|IGF-1]] is a [[protein]] responsible for most of the growth-promoting activities of [[Growth hormone|GH]].
* [[Insulin-like growth factor-I|IGF-1]] directly inhibits [[Growth hormone|GH]] secretion and GH [[Receptor (biochemistry)|receptor]] function by a negative feedback effect.
* [[Growth hormone|GH]] stimulates [[cell proliferation]] in [[osteoblasts]]. Human [[Trabecular bone|trabecular]] [[osteoblasts]] produce mainly [[Insulin-like growth factor 2|IGF-II]], IGFBP-3 and fewer quantities of [[IGF-I]] in culture.
* IGFs and their binding [[proteins]] may exert important regulatory effects on the [[Growth hormone|GH]] effect on [[osteoblasts]].
[[File:Growth liver.png|300px|center|thumb| Growth hormone peripheral action, source: By Mikael Häggström.When using this image in external works, it may be cited asHäggström, Mikael (2014). Medical gallery of Mikael Häggström 2014. WikiJournal of Medicine 1 (2). DOI10.15347wjm2014.008. ISSN 2002-4436]]


a homozygous missense mutation in the gene encoding signal transducer and activator transcription 5B (STAT5B) which is essential for normal signaling of the GH receptor [15-18].
== Growth Hormone signaling ==
* A single [[Growth hormone|GH]] molecule binds with two GH [[Receptor (biochemistry)|receptor]] molecules, followed by activation of [[Janus kinase|JAK2 tyrosine kinase]] by [[phosphorylation]].
* [[Phosphorylation]] of [[JAK2]] leads to [[phosphorylation]] of intracellular proteins called [[STAT protein|STAT proteins]], [[MAP kinases|MAP kinase]] activation, and induction of [[gene expression]].
* These [[STAT protein|STAT proteins]] are [[phosphorylated]] by [[JAK2]] and directly translocated to the [[cell nucleus]], where they play the major control of [[Growth hormone|GH]]-specific [[gene]] effects by binding to [[nuclear DNA]].
* [[STAT5]] plays an important role in the regulation of expression of some [[Gene|genes]] in the [[liver]] [[Cell (biology)|cells.]]
* A defect in [[Growth hormone|GH]]-mediated [[JAK-STAT signaling pathway|JAK-STAT]] signal [[transduction]] could be a cause of the [[Growth hormone|GH]] resistance.
[[File:Growth Hormone-pathway-3.gif|350px|center|thumb|GH signaling]]


'''IGF-I gene mutations''' 
==Genetic basis of growth hormone deficiency==
==== ''[[POU1F1]]'' gene mutations ====
* This is the most common known genetic cause of the combined [[Pituitary gland|pituitary]] hormone deficiency.<ref name="pmid26608600">{{cite journal| author=Ziemnicka K, Budny B, Drobnik K, Baszko-Błaszyk D, Stajgis M, Katulska K et al.| title=Two coexisting heterozygous frameshift mutations in PROP1 are responsible for a different phenotype of combined pituitary hormone deficiency. | journal=J Appl Genet | year= 2016 | volume= 57 | issue= 3 | pages= 373-81 | pmid=26608600 | doi=10.1007/s13353-015-0328-z | pmc=4963446 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26608600  }}</ref>
* It is responsible for [[Pituitary gland|pituitary]]-specific [[Transcription (genetics)|transcription]] of [[Gene|genes]] for GH, [[prolactin]], [[thyrotropin]], and the [[growth hormone releasing hormone|growth hormone-releasing hormone]] ([[GHRH]]) receptor.<ref name="pmid1977085">{{cite journal| author=Li S, Crenshaw EB, Rawson EJ, Simmons DM, Swanson LW, Rosenfeld MG| title=Dwarf locus mutants lacking three pituitary cell types result from mutations in the POU-domain gene pit-1. | journal=Nature | year= 1990 | volume= 347 | issue= 6293 | pages= 528-33 | pmid=1977085 | doi=10.1038/347528a0 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1977085  }}</ref>
* ''PROP1'' [[mutations]] result in failure to activate ''POU1F1/Pit1'' [[gene expression]] and probably cause [[Pituitary gland|pituitary]] hypoplasia.<ref name="pmid9462743">{{cite journal| author=Wu W, Cogan JD, Pfäffle RW, Dasen JS, Frisch H, O'Connell SM et al.| title=Mutations in PROP1 cause familial combined pituitary hormone deficiency. | journal=Nat Genet | year= 1998 | volume= 18 | issue= 2 | pages= 147-9 | pmid=9462743 | doi=10.1038/ng0298-147 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9462743  }}</ref>


Mutations in the gene encoding IGF-I cause a unique syndrome of GHD  21-23
==== GH1 gene mutations ====
* ''GH1'' gene encoding GH is located on [[chromosome 17]].
* [[Gene deletion|Gene deletions]], f[[Frameshift mutation|rameshift]] mutations, and [[nonsense mutations]] of ''GH1'' have been described as causes of familial GHD.


patients with IGF-I gene mutations have prenatal growth failure, microcephaly, significant neurocognitive deficits, sensorineural hearing loss 21
==== Syndrome of bioinactive GH ====
* Bioinactive GH has the main symptoms and signs of isolated GHD with normal basal GH levels and low [[Insulin-like growth factor 1|insulin-like growth factor I]] concentrations.<ref name="pmid15713716">{{cite journal| author=Besson A, Salemi S, Deladoëy J, Vuissoz JM, Eblé A, Bidlingmaier M et al.| title=Short stature caused by a biologically inactive mutant growth hormone (GH-C53S). | journal=J Clin Endocrinol Metab | year= 2005 | volume= 90 | issue= 5 | pages= 2493-9 | pmid=15713716 | doi=10.1210/jc.2004-1838 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15713716  }}</ref>


'''Defective stabilization of circulating IGF-I''' 
==== '''GH receptor signal [[transduction]]''' ====
* It is essential for normal signaling of the GH receptor. Mutations in the gene encoding signal transducer decrease the response of receptors to [[Growth hormone|GH]].<ref name="pmid17389811">{{cite journal| author=Hwa V, Camacho-Hübner C, Little BM, David A, Metherell LA, El-Khatib N et al.| title=Growth hormone insensitivity and severe short stature in siblings: a novel mutation at the exon 13-intron 13 junction of the STAT5b gene. | journal=Horm Res | year= 2007 | volume= 68 | issue= 5 | pages= 218-24 | pmid=17389811 | doi=10.1159/000101334 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17389811  }}</ref>


deficiency of acid-labile subunit (ALS) which is important for the stabilization of the IGF-I-IGFBP-3 complex, forming a three-part (ternary) complex in the circulation. [25,26].  
==== '''[[Insulin-like growth factor-I|IGF-I]] gene mutations''' ====
* Mutations in the gene encoding [[Insulin-like growth factor-I|IGF-I]] cause a unique syndrome of GHD.<ref name="pmid24243634">{{cite journal| author=Batey L, Moon JE, Yu Y, Wu B, Hirschhorn JN, Shen Y et al.| title=A novel deletion of IGF1 in a patient with idiopathic short stature provides insight Into IGF1 haploinsufficiency. | journal=J Clin Endocrinol Metab | year= 2014 | volume= 99 | issue= 1 | pages= E153-9 | pmid=24243634 | doi=10.1210/jc.2013-3106 | pmc=3879666 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24243634  }}</ref>
* Patients with [[Insulin-like growth factor-I|IGF-I]] [[Gene mutation|gene mutations]] have prenatal growth failure, [[microcephaly]], significant [[Neurocognitive deficit|neurocognitive deficits]], and [[sensorineural hearing loss]].


'''IGF-I receptor mutations''' 
==== '''Defective stabilization of circulating [[Insulin-like growth factor-I|IGF-I]]''' ====
* Acid-labile subunit is important for the stabilization of the [[Insulin-like growth factor-I|IGF-I]].
* [[Mutations]] in the [[gene]] coding for it causes less stable and subsequently less effective end product.<ref name="pmid19729943">{{cite journal| author=Domené HM, Hwa V, Argente J, Wit JM, Wit JM, Camacho-Hübner C et al.| title=Human acid-labile subunit deficiency: clinical, endocrine and metabolic consequences. | journal=Horm Res | year= 2009 | volume= 72 | issue= 3 | pages= 129-41 | pmid=19729943 | doi=10.1159/000232486 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19729943  }}</ref>


Mutations in the gene encoding the receptor for IGF-I have been reported in infants presenting with pre- and postnatal growth failure [27-30].
==== '''[[Insulin-like growth factor-I|IGF-I]] receptor mutations''' ====
 
* [[Mutations]] in the [[gene]] encoding the receptor for the [[Insulin-like growth factor-I|IGF-I]] result in partial loss of function of the [[Insulin-like growth factor-I|IGF-I]] receptor.<ref name="pmid22309212">{{cite journal| author=Kawashima Y, Higaki K, Fukushima T, Hakuno F, Nagaishi J, Hanaki K et al.| title=Novel missense mutation in the IGF-I receptor L2 domain results in intrauterine and postnatal growth retardation. | journal=Clin Endocrinol (Oxf) | year= 2012 | volume= 77 | issue= 2 | pages= 246-54 | pmid=22309212 | doi=10.1111/j.1365-2265.2012.04357.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22309212  }}</ref>
These mutations are thought to result in partial loss of function of the IGF-I receptor
 
==Associated Conditions==


==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
{{WH}}
{{WS}}
[[Category:Disease]]
[[Category:Endocrinology]]

Latest revision as of 16:15, 30 October 2017

Growth hormone deficiency Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Growth hormone deficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Growth hormone deficiency pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Growth hormone deficiency pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Growth hormone deficiency pathophysiology

CDC on Growth hormone deficiency pathophysiology

Growth hormone deficiency pathophysiology in the news

Blogs on Growth hormone deficiency pathophysiology

Directions to Hospitals Treating Growth hormone deficiency

Risk calculators and risk factors for Growth hormone deficiency pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohammed Abdelwahed M.D[2]

Overview

The somatotroph cells of the anterior pituitary organ produce growth hormone (GH). The most widely studied impact of growth hormone is increasing weight. GH causes epiphyseal plate broadening and ligament development. GH deficiency results in alterations in the physiology of different systems of the body, manifesting as altered lipid metabolism, increased subcutaneous visceral fat, decreased muscle mass, decreased bone density, low exercise performance, and reduced quality of life. The hereditary premise of inborn growth hormone deficiency relies upon numerous factors; POU1F1 quality transformations are the most widely recognized hereditary reason for the joined pituitary hormone lack. Quality deletions, frameshift transformations, and jabber changes of GH1 quality have been described as reasons for familial GHD.

Pathophysiology

Regulation of growth hormone secretion

Growth hormone secretion regulations, source: By OpenStax College - Anatomy & Physiology, Connexions Web site. httpcnx.orgcontentcol114961.6, Jun 19, 2013., CC BY 3.0, httpscommons.wikimedia.orgwindex.phpcurid=30148146

Molecular effects of growth hormone on cells

Growth hormone peripheral action, source: By Mikael Häggström.When using this image in external works, it may be cited asHäggström, Mikael (2014). Medical gallery of Mikael Häggström 2014. WikiJournal of Medicine 1 (2). DOI10.15347wjm2014.008. ISSN 2002-4436

Growth Hormone signaling

GH signaling

Genetic basis of growth hormone deficiency

POU1F1 gene mutations

GH1 gene mutations

Syndrome of bioinactive GH

GH receptor signal transduction

  • It is essential for normal signaling of the GH receptor. Mutations in the gene encoding signal transducer decrease the response of receptors to GH.[8]

IGF-I gene mutations

Defective stabilization of circulating IGF-I

  • Acid-labile subunit is important for the stabilization of the IGF-I.
  • Mutations in the gene coding for it causes less stable and subsequently less effective end product.[10]

IGF-I receptor mutations

References

  1. ↑ Cuttler L (1996). "The regulation of growth hormone secretion". Endocrinol Metab Clin North Am. 25 (3): 541–71. PMID 8879986.
  2. ↑ MURPHY WR, DAUGHADAY WH, HARTNETT C (1956). "The effect of hypophysectomy and growth hormone on the incorporation of labeled sulfate into tibial epiphyseal and nasal cartilage of the rat". J Lab Clin Med. 47 (5): 715–22. PMID 13319878.
  3. ↑ Veldhuis JD, Roemmich JN, Richmond EJ, Rogol AD, Lovejoy JC, Sheffield-Moore M; et al. (2005). "Endocrine control of body composition in infancy, childhood, and puberty". Endocr Rev. 26 (1): 114–46. doi:10.1210/er.2003-0038. PMID 15689575.
  4. ↑ Ziemnicka K, Budny B, Drobnik K, Baszko-Błaszyk D, Stajgis M, Katulska K; et al. (2016). "Two coexisting heterozygous frameshift mutations in PROP1 are responsible for a different phenotype of combined pituitary hormone deficiency". J Appl Genet. 57 (3): 373–81. doi:10.1007/s13353-015-0328-z. PMC 4963446. PMID 26608600.
  5. ↑ Li S, Crenshaw EB, Rawson EJ, Simmons DM, Swanson LW, Rosenfeld MG (1990). "Dwarf locus mutants lacking three pituitary cell types result from mutations in the POU-domain gene pit-1". Nature. 347 (6293): 528–33. doi:10.1038/347528a0. PMID 1977085.
  6. ↑ Wu W, Cogan JD, Pfäffle RW, Dasen JS, Frisch H, O'Connell SM; et al. (1998). "Mutations in PROP1 cause familial combined pituitary hormone deficiency". Nat Genet. 18 (2): 147–9. doi:10.1038/ng0298-147. PMID 9462743.
  7. ↑ Besson A, Salemi S, Deladoëy J, Vuissoz JM, Eblé A, Bidlingmaier M; et al. (2005). "Short stature caused by a biologically inactive mutant growth hormone (GH-C53S)". J Clin Endocrinol Metab. 90 (5): 2493–9. doi:10.1210/jc.2004-1838. PMID 15713716.
  8. ↑ Hwa V, Camacho-Hübner C, Little BM, David A, Metherell LA, El-Khatib N; et al. (2007). "Growth hormone insensitivity and severe short stature in siblings: a novel mutation at the exon 13-intron 13 junction of the STAT5b gene". Horm Res. 68 (5): 218–24. doi:10.1159/000101334. PMID 17389811.
  9. ↑ Batey L, Moon JE, Yu Y, Wu B, Hirschhorn JN, Shen Y; et al. (2014). "A novel deletion of IGF1 in a patient with idiopathic short stature provides insight Into IGF1 haploinsufficiency". J Clin Endocrinol Metab. 99 (1): E153–9. doi:10.1210/jc.2013-3106. PMC 3879666. PMID 24243634.
  10. ↑ Domené HM, Hwa V, Argente J, Wit JM, Wit JM, Camacho-Hübner C; et al. (2009). "Human acid-labile subunit deficiency: clinical, endocrine and metabolic consequences". Horm Res. 72 (3): 129–41. doi:10.1159/000232486. PMID 19729943.
  11. ↑ Kawashima Y, Higaki K, Fukushima T, Hakuno F, Nagaishi J, Hanaki K; et al. (2012). "Novel missense mutation in the IGF-I receptor L2 domain results in intrauterine and postnatal growth retardation". Clin Endocrinol (Oxf). 77 (2): 246–54. doi:10.1111/j.1365-2265.2012.04357.x. PMID 22309212.
Retrieved from "https://www.wikidoc.org/index.php?title=Growth_hormone_deficiency_pathophysiology&oldid=1381516"